文献速递前列腺癌

前列腺穿刺活检阴性的预后意义:一项前列腺癌筛查试验入组对象的分析

Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial.
PubMed 文献 · J Urol · 2016-11-08

基于PLCO筛查试验数据,纳入初筛阳性后行前列腺活检的4064例受试者,其中473例活检阳性、760例阴性。中位随访12.9年,活检阴性队列前列腺癌特异性死亡率为1.1%,其相对对照组的亚风险比为2.93(95%CI 1.44-5.99)。作者认为活检阴性者前列腺癌死亡风险相对较低。

要点

  • 初筛阳性后活检阴性者中位随访12.9年前列腺癌特异性死亡率为1.1%。
  • 活检阴性者相对对照组的亚风险比为2.93(95%CI 1.44-5.99)。
  • 活检阳性者相对对照组的亚风险比为18.77(95%CI 12.62-27.93)。

核心结论

  • 前列腺活检阴性后,在传统标志物和活检技术随访下,男性死于前列腺癌的风险相对较低。
  • 作者认为这一结果提示新的诊断干预在该组中改善生存的潜力有限。

研究设计与样本

  • 基于PLCO(前列腺、肺、结直肠和卵巢癌)筛查试验的生存数据分析。
  • 筛查组36525例、对照组36560例。
  • 初筛阳性者4064例,其中1233例行关联活检,473例阳性、760例阴性。
  • 中位随访12.9年。

主要发现

  • 活检阴性队列前列腺癌特异性死亡率为1.1%。
  • 活检阴性组与对照组死亡率差异为每1000人年0.734例死亡。
  • 活检阴性组相对对照组的亚风险比为2.93(95%CI 1.44-5.99)。
  • 活检阳性组相对对照组的亚风险比为18.77(95%CI 12.62-27.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To our knowledge the optimal treatment of patients following a negative prostate biopsy is unknown. Consequently, resources are increasingly being directed toward risk stratification in this cohort. However, the risk of prostate cancer mortality in this group before the introduction of supplemental biomarkers and imaging techniques is unclear. MATERIALS AND METHODS: The PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) Screening Trial provides survival data prior to the implementation of new diagnostic interventions. We divided men with an initial positive screen and a subsequent prostate biopsy into cohorts based on positive or negative results. Prostate cancer specific mortality was then compared to that in the trial control arm to estimate the prognostic significance of biopsy results relative to the general population. RESULTS: A total of 36,525 and 36,560 patients comprised the screening and control arms, respectively. Of 4,064 subjects with a positive first screen 1,233 underwent a linked biopsy, of which 473 were positive and 760 were negative. At a median followup of 12.9 years, 1.1% of men in the negative biopsy cohort had died of prostate cancer. The difference in mortality rates between the negative biopsy and control arms was 0.734 deaths per 1,000 person-years. The proportional subhazard ratios of prostate cancer specific mortality for negative biopsy and positive biopsy relative to the control arm were 2.93 (95% CI 1.44-5.99) and 18.77 (95% CI 12.62-27.93), respectively. CONCLUSIONS: After a negative prostate biopsy, men face a relatively low risk of death from prostate cancer when followed with traditional markers and biopsy techniques. This suggests limited potential for new diagnostic interventions to improve survival in this group.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lewicki P, Shoag J, Golombos DM, et al. Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial. J Urol. 2016. PMID: 27836710. doi:10.1016/j.juro.2016.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。